| HOME >> BIOLOGY >> TECHNOLOGY |
ROCKLAND, Mass., April 16 /PRNewswire/ -- Merck Serono and its US affiliate EMD Serono, Inc., both part of Merck KGaA, Darmstadt, Germany, announced today a planned expansion of EMD Serono's US presence with an anticipated investment of $50 million at its Billerica facility northwest of Boston, Massachusetts. The company anticipates that this investment will create more than 100 new jobs in Massachusetts.
The investment will support the construction of a center of excellence in discovery, creating critical mass in research with a common goal of finding new treatments for unmet medical needs.
"This announcement reflects Merck KGaA's strong commitment to expand EMD Serono and anchor our US operations in Massachusetts," said Elmar Schnee, Member of the Executive Board Merck KGaA and Head of Pharmaceuticals. "We recognize the significant value of augmenting our research capabilities in Boston-a region with tremendous life-sciences influence not only across the US, but also globally."
Once complete, the new site will accommodate approximately 200 scientists with expertise in cancer biology, cancer immunotherapy, oncogene signaling, manufacturing cell lines, medicinal chemistry, molecular modeling, protein engineering, and therapeutic antibodies, across the research areas of cancer and fertility, as well as approximately 50 employees in Technical Operations who specialize in process development and protein production.
The company's protein production facility in Billerica, which manufactures products for early stage clinical testing, is a significant reason why the site was selected for expansion; the close proximity of protein production to research drives collaborative interactions and supports the rapid transition from research to manufacturing.
"This investment demonstrates the value of our US operations as a
crucial component of the global organization's long-term success," says
Fereydoun Firouz, CEO and President of EMD Sero
'/>"/>
| SOURCE EMD Serono, Inc. Copyright©2008 PR Newswire. All rights reserved |